# Eric P. Krenning

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/eric-p-krenning/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,348 |
| Field | Neuroendocrine Tumor Research Advances |
| h-index | 95 |
| i10-index | 244 |
| Last Known Institution | Erasmus MC |
| OpenAlex ID | https://openalex.org/A5110041975 |
| Works | 355 |

## Researcher papers

- [Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Gastroenteropancreatic neuroendocrine tumours](https://scholariq.org/papers/gastroenteropancreatic-neuroendocrine-tumours/)
- [ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary](https://scholariq.org/papers/enets-consensus-guidelines-for-the-management-of-patients-with-liver-and-other/)
- [Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids](https://scholariq.org/papers/pulmonary-neuroendocrine-carcinoid-tumors-european-neuroendocrine-tumor-society/)
- [Long-Term Efficacy, Survival, and Safety of \[177Lu-DOTA0,Tyr3\]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors](https://scholariq.org/papers/long-term-efficacy-survival-and-safety-of-177lu-dota0-tyr3-octreotate-in/)
- [ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging](https://scholariq.org/papers/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-tumors/)
- [Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors](https://scholariq.org/papers/long-term-tolerability-of-prrt-in-807-patients-with-neuroendocrine-tumours-the/)
- [Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial](https://scholariq.org/papers/health-related-quality-of-life-in-patients-with-progressive-midgut/)
- [Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.](https://scholariq.org/papers/overview-of-results-of-peptide-receptor-radionuclide-therapy-with-3-radiolabeled/)
- [ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues](https://scholariq.org/papers/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-neoplasms/)
- [\[<sup>123</sup>I\]Metaiodobenzylguanidine and\[<sup>111</sup>In\]Octreotide Uptake in Benign and Malignant Pheochromocytomas<sup>1</sup>](https://scholariq.org/papers/sup-123-sup-i-metaiodobenzylguanidine-and-sup-111-sup-in-octreotide-uptake-in/)

## Researcher topics

- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Erasmus MC](https://scholariq.org/institutions/erasmus-mc/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.